<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="9ba29f67-83be-4715-8a6b-e27347a47a80"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use REVUFORJ safely and effectively. See full prescribing information for REVUFORJ.</content>
      <br/>
      <br/>
      <content styleCode="bold">Revuforj (revumenib) tablets for oral use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2024</content>
   </title>
   <effectiveTime value="20250417"/>
   <setId root="6eb3cdbc-0e74-477d-82d6-3bb172d3f63f"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="119075871" root="1.3.6.1.4.1.519.1"/>
            <name>Syndax Pharmaceuticals, Inc.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="6f416635-5d30-46c1-8066-069572b62828"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241119"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73555-500" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Revuforj</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>revumenib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="25" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YL4RYN734D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>revumenib citrate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LZ0M43NNF2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>revumenib</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="73555-500-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20241115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20241115"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">S;25</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73555-501" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Revuforj</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>revumenib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="110" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YL4RYN734D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>revumenib citrate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LZ0M43NNF2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>revumenib</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="73555-501-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20241115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20241115"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>Beige</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">S;110</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73555-502" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Revuforj</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>revumenib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="160" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YL4RYN734D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>revumenib citrate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LZ0M43NNF2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>revumenib</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="73555-502-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20241115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20241115"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PURPLE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="17" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">S;160</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="e477ea0a-d0b1-426f-bdf0-5257c6ed4510"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: DIFFERENTIATION SYNDROME </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Differentiation syndrome, which can be fatal, has occurred with REVUFORJ. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: DIFFERENTIATION SYNDROME</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Differentiation syndrome, which can be fatal, has occurred with REVUFORJ. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution (<linkHtml href="#S5.1">5.1</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="a8e071a4-5fdd-4184-ba63-3da87e7fce05"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20241111"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="31b4e9e5-f5cc-4dbd-b962-7e2b9037ec27"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Relapsed or Refractory Acute Leukemia</content>
                        </paragraph>
                        <paragraph>REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.</paragraph>
                     </text>
                     <effectiveTime value="20241111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="7d428f4f-aa01-44c8-af04-34239e991b7c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Select patients for treatment with REVUFORJ based on the presence of a KMT2A translocation. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Administer REVUFORJ orally twice daily fasted or with a low-fat meal at approximately the same time each day. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>See Full Prescribing Information for recommended REVUFORJ dosage regimen, dosage modifications, and administration instructions. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="8efab687-d7f5-410d-8b43-141edbb33391"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Patient Selection</title>
                     <text>
                        <paragraph>Select patients for the treatment of acute leukemia with REVUFORJ based on the presence of a KMT2A translocation in bone marrow cells<content styleCode="italics"> [see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. An FDA-approved companion diagnostic for the detection of a KMT2A translocation is not currently available.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="bdfa8d6f-bf6c-4465-b8db-99f4f88813f0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of REVUFORJ varies by patient weight and concomitant use of strong CYP3A4 inhibitors. See Table 1 for the recommended dosage for patients 1 year and older. Do not start REVUFORJ until the WBC is reduced to less than 25 Gi/L. Continue REVUFORJ until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.</paragraph>
                        <table width="100%">
                           <caption>Table 1. REVUFORJ Recommended Dosage for Patients 1 Year and Older </caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3"> *See Table 2 for the total tablet dosage by BSA (body surface area) for patients weighing less than 40 kg.  </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Patient Weight</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Without Strong CYP3A4 Inhibitors</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">With Strong CYP3A4 Inhibitors</content>
                                 </td>
                              </tr>
                              <tr align="center">
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">40 kg or more</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">270 mg orally twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">160 mg orally twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Less than 40 kg</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">160 mg/m<sup>2</sup> orally twice daily*</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">95 mg/m<sup>2</sup> orally twice daily*</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%">
                           <caption>Table 2: Recommended Dosage using Tablets* for Patients Weighing Less than 40 kg </caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3"> * If needed, attain the desired dose by combining different strengths of REVUFORJ tablets.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">BSA (m<sup>2</sup>)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> REVUFORJ Dosage for 160 mg/m<sup>2</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> REVUFORJ Dosage for 95 mg/m<sup>2</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1.4</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 220 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">135 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1.3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> 220 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">135 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1.2</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">185 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">110 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left">1.1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">185 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">110 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">160 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">100 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.9</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">135 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.8</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">135 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.7</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">110 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.6</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">100 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.5</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.4</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">25 mg twice daily</td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>If the strong CYP3A4 inhibitor is discontinued, increase the REVUFORJ dose after at least 5 half-lives of the strong CYP3A4 inhibitor to the recommended dosage without strong CYP3A4 inhibitors (Table 1).</item>
                           <item>Concurrent use of standard intrathecal chemotherapy prophylaxis is recommended for patients with risk of central nervous system relapse.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">
                              <content styleCode="bold">Administration:</content>
                           </content>
                        </paragraph>
                        <paragraph/>
                        <list listType="unordered">
                           <item>Administer REVUFORJ twice daily fasted or with a low-fat meal (e.g., meals with approximately 400 calories, 25% or less fat).</item>
                           <item>Administer REVUFORJ orally around the same time each day.</item>
                           <item>Advise patients to swallow tablets whole and to not cut or chew tablets. If patients are unable to swallow tablets, they may be crushed and dispersed in water and taken within 2 hours of preparation [see Instructions for Use].</item>
                           <item>If a dose of REVUFORJ is missed or not taken at the usual time, administer the dose as soon as possible on the same day and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="44e4e590-3ff9-421c-8d8c-f71f6ae7f177"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>Assess blood counts, electrolytes, and liver enzymes prior to the initiation of REVUFORJ and monthly thereafter. Perform an electrocardiogram (ECG) prior to the initiation of REVUFORJ, at least once a week for the first 4 weeks, and at least monthly thereafter. Monitor for QTc interval prolongation and manage any abnormalities promptly [see <content styleCode="italics">
                              <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Interrupt dosing or reduce dose for adverse reactions as per Table 3. Dose levels for dose reductions are listed in Table 4, Table 5, and Table 6.</paragraph>
                        <table width="100%">
                           <caption>Table 3. Recommended Management and Dosage Modifications for Adverse Reactions </caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="2" valign="top">*Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening. Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0).<br/>**See Tables 4, 5 and 6 for the reduced dose levels.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold"> Adverse reaction</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold"> Recommended action</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left">Differentiation Syndrome [see <content styleCode="italics">
                                       <linkHtml href="http://form.html#S5.1">Warnings and Precautions (5.1)</linkHtml>
                                    </content>]</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days. [<content styleCode="italics">see<linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>
                                          </content>].</item>
                                       <item>Interrupt REVUFORJ if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier for life-threatening symptoms such as pulmonary symptoms requiring ventilator support [<content styleCode="italics">see<linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>
                                          </content>]. Resume REVUFORJ at the same dose when signs and symptoms improve to Grade 1* or lower.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Noninfectious leukocytosis</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Initiate treatment with hydroxyurea in patients with an elevated or rapidly rising leukocyte count. Add leukapheresis if clinically indicated.</item>
                                       <item>Taper hydroxyurea only after leukocytosis improves or resolves.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">QTc interval greater than 480 msec to 500 msec [<content styleCode="italics">see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>
                                    </content>]</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Interrupt REVUFORJ.</item>
                                       <item>Check electrolyte levels. Correct hypokalemia and hypomagnesemia [<content styleCode="italics">see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>
                                          </content>].</item>
                                       <item>Restart REVUFORJ at the same dose level after the QTc interval returns to less than or equal to 480 msec.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">QTc interval greater than 500 msec (Grade 3*) [<content styleCode="italics">see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>
                                    </content>]</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Interrupt REVUFORJ.</item>
                                       <item>Check electrolyte levels. Correct hypokalemia and hypomagnesemia [<content styleCode="italics">see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>
                                          </content>].</item>
                                       <item>Restart REVUFORJ at the reduced dose level** after the QTc interval returns to less than or equal to 480 msec.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">QTc interval prolongation with signs/symptoms of life-threatening arrhythmia, Torsades de pointes, polymorphic ventricular tachycardia, signs/ symptoms of life-threatening arrhythmia (Grade 4*) [<content styleCode="italics">see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>
                                    </content>].</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item> Permanently discontinue REVUFORJ.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Potassium 3.6-3.9 mEq/L, and/or<br/>Magnesium 1.7-1.9 mg/dL or 0.66-0.81 mmol/L</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Supplement potassium and/or magnesium.</item>
                                       <item>Continue REVUFORJ.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Potassium ≤ 3.5 mEq/L, and/or<br/>Magnesium ≤ 1.6 mg/dL or ≤ 0.65 mmol/L</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Supplement potassium and/or magnesium, and recheck levels within 24 hours.</item>
                                       <item>On recheck of potassium and magnesium labs within 24 hours, if potassium is greater than 3.5 mEq/L and/or magnesium is greater than 1.6 mg/dL, continue REVUFORJ. If potassium is less than 3.5 mEq/L and/or magnesium is less than 1.6 mg/dL, hold REVUFORJ and continue supplementation; resume REVUFORJ at the same dose level when the correction is complete.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Other nonhematological adverse reactions Grade ≥ 3* [<content styleCode="italics">see<linkHtml href="#S6.1"> Adverse Reactions (6.1)</linkHtml>
                                    </content>]</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Interrupt REVUFORJ until recovery to Grade 1* or baseline.</item>
                                       <item>If recovered in ≤ 7 days, restart REVUFORJ at the same dose level. If the same Grade ≥ 3* toxicity recurs, interrupt REVUFORJ until recovery to Grade 1* or baseline. Restart REVUFORJ at the reduced dose level.**<br/>If recovered in &gt; 7 days, restart REVUFORJ at the reduced dose level.** If the same Grade ≥ 3* toxicity recurs, discontinue REVUFORJ.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Grade 4* neutropenia or thrombocytopenia [<content styleCode="italics">see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                                    </content>]</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Interrupt REVUFORJ until recovery to Grade ≤ 2* or baseline.</item>
                                       <item>Restart REVUFORJ at the same dose level.</item>
                                       <item>If Grade 4* neutropenia or thrombocytopenia recurs without attributable cause, interrupt REVUFORJ until recovery to Grade ≤ 3*. Restart REVUFORJ at the reduced dose level.**</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Grade 3* or higher allergic reactions [see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item> Permanently discontinue REVUFORJ.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <table width="100%">
                           <caption>Table 4. REVUFORJ Dosage Reduction for Adverse Reactions in Patients NOT on Strong CYP3A4 Inhibitors </caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3" align="left">**See <content styleCode="bold">Table 6</content> for BSA-based dosage recommendations for the reduced dosage of 95 mg/m<sup>2</sup> twice daily.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Patients Weighing 40 kg or Greater</content>
                                    <br/>
                                    <content styleCode="bold">at Starting Dose 270 mg</content>
                                    <br/>
                                    <content styleCode="bold">orally twice daily</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Patients Weighing Less Than 40 kg</content>
                                    <br/>
                                    <content styleCode="bold">at Starting Dose 160 mg/m<sup>2</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">orally twice daily</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center"> Reduced Dose</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">160 mg orally twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">95 mg/m<sup>2</sup> orally twice daily*</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <table width="100%">
                           <caption>Table 5. REVUFORJ Dosage Reduction for Adverse Reactions in Patients on Strong CYP3A4 Inhibitors </caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3">*See <content styleCode="bold">Table 6</content> for BSA-based dosage recommendations for the reduced dosage of 65 mg/m<sup>2</sup> twice daily.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Patients Weighing 40 kg or Greater</content>
                                    <br/>
                                    <content styleCode="bold">at Starting Dose 160 mg</content>
                                    <br/>
                                    <content styleCode="bold">orally twice daily</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Patients Weighing Less Than 40 kg</content>
                                    <br/>
                                    <content styleCode="bold">at Starting Dose 95 mg/m<sup>2</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">orally twice daily</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">Reduced Dose</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">110 mg orally twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">65 mg/m<sup>2</sup> orally twice daily*</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%">
                           <caption>Table 6: Recommended Reduced Dosage Using Tablets* for Patients Weighing Less than 40 kg </caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3"> * If needed, attain the desired dose by combining different strengths of REVUFORJ tablets.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold"> BSA (m<sup>2</sup>)</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> REVUFORJ Dosage for 95 mg/m<sup>2</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> REVUFORJ Dosage for 65 mg/m<sup>2</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1.4</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">135 mg twice daily</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">100 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1.3 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">135 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1.2 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">110 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left">1.1 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">110 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">100 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.9 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.8 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">75 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.7 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.6 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">25 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.5 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">25 mg twice daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.4 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">25 mg twice daily </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">25 mg twice daily </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="33bec476-eb3c-4f93-b5ff-3920e3c2cc7c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20241119"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Tablets: 25 mg, 110 mg, 160 mg (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="99dbd351-7512-48c3-866c-5a6e843acd3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Tablets:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>25 mg of revumenib: Pink modified oval film-coated tablet debossed with “S” on one side and “25” on the other side.</item>
                           <item>110 mg of revumenib: Beige modified oval film-coated tablet debossed with “S” on one side and “110” on the other side.</item>
                           <item>160 mg of revumenib: Purple modified oval film-coated tablet debossed with “S” on one side and “160” on the other side.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="98f91a06-ef4e-4898-9faa-e1e570c5f4d9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20241112"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>None. (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="4071a099-eefd-46b9-bbde-4af28f3dff27"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">QTc Interval Prolongation:</content> Monitor electrocardiograms and electrolytes. Correct hypokalemia and hypomagnesemia prior to and during treatment. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue REVUFORJ. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of potential risk to a fetus and to use effective contraception. (<linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="57cd936b-639b-42f7-8b6e-66faa3537ee4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Differentiation Syndrome</title>
                     <text>
                        <paragraph>REVUFORJ can cause fatal or life-threatening differentiation syndrome (DS). Symptoms of differentiation syndrome, including those seen in patients treated with REVUFORJ, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, and/or hypotension.</paragraph>
                        <paragraph>In clinical trials, DS occurred in 39 (29%) of 135 patients treated with REVUFORJ at the recommended dosage for relapsed or refractory acute leukemia with a KMT2A translocation, including 32% of patients with acute myeloid leukemia (AML), 25% of patients with mixed-phenotype acute leukemia (MPAL), and 14% of patients with acute lymphoblastic leukemia (ALL). DS was Grade 3 or 4 in 13% and fatal in one patient. The median time to onset was 10 days (range 3-41 days). Some patients experienced more than 1 DS event. Treatment interruption was required for 7% of patients, and treatment was withdrawn for 1% [<content styleCode="italics">see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Reduce the white blood cell count (WBC) to less than 25 Gi/L prior to starting REVUFORJ. If DS is suspected, immediately initiate treatment with systemic corticosteroids (e.g., dexamethasone 10 mg intravenously every 12 hours in adults or dexamethasone 0.25 mg/kg/dose intravenously every 12 hours in pediatric patients weighing less than 40 kg) for a minimum of 3 days and until resolution of signs and symptoms. Institute supportive measures and hemodynamic monitoring until improvement. Interrupt REVUFORJ if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support. Restart steroids promptly if DS recurs after tapering corticosteroids [see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="294b77b3-06bd-4535-afdc-4a2112b5d4d6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  QTc Interval Prolongation</title>
                     <text>
                        <paragraph>REVUFORJ can cause QT (QTc) interval prolongation [see <content styleCode="italics">
                              <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>
                           </content>]. In the clinical trials, QTc interval prolongation was reported as an adverse reaction in 39 (29%) of 135 patients treated with REVUFORJ at the recommended dosage for relapsed or refractory acute leukemia with a KMT2A translocation; QTc interval prolongation was Grade 3 in 12%. The heart-rate corrected QT interval (using Fridericia’s method) (QTcF) was greater than 500 msec in 8%, and the increase from baseline QTcF was greater than 60 msec in 18%. REVUFORJ dose reduction was required for 5% due to QTc interval prolongation [see <content styleCode="italics">
                              <linkHtml href="#S6.1">Adverse Reactions (6.1</linkHtml>
                              <linkHtml href="#S6.1">)</linkHtml>
                           </content>]. QTc prolongation occurred in 16% of the 31 patients less than 17 years old, 33% of the 88 patients 17 years to less than 65 years old, and in 50% of the 16 patients 65 years or older.</paragraph>
                        <paragraph>Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with REVUFORJ. Perform an ECG prior to initiation of treatment with REVUFORJ, and do not initiate REVUFORJ in patients with QTcF &gt; 450 msec. Perform an ECG at least once a week for the first 4 weeks on treatment, and at least monthly thereafter [see <content styleCode="italics">
                              <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>
                           </content>]. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use of REVUFORJ with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation [see <content styleCode="italics">
                              <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>, <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Interrupt REVUFORJ if QTcF increases to greater than 480 msec and less than 500 msec, and restart REVUFORJ at the same dose twice daily after the QTcF interval returns to less than or equal to 480 msec. Interrupt REVUFORJ if QTcF increases to greater than 500 msec or by &gt; 60 msec from baseline, and restart REVUFORJ twice daily at the lower dose level after the QTcF interval returns to less than or equal to 480 msec. Permanently discontinue REVUFORJ in patients with ventricular arrhythmias and in those who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia [see <content styleCode="italics">
                              <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="9ceaaccf-1fd5-415c-a7f1-a5d27cc62b01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>
                           <content>Based on findings in animals and its mechanism of action, REVUFORJ can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, oral administration of revumenib to pregnant rats during the period of organogenesis caused adverse developmental outcomes, including embryo-fetal mortality, malformations, and altered fetal growth at maternal exposures approximately 0.5 times the human exposure (AUC) at the recommended dose.</content>
                        </paragraph>
                        <paragraph>
                           <content>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with REVUFORJ and for 4 months after the last dose [</content>
                           <content styleCode="italics">see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="a418c9bb-da72-4371-98db-1a463c7f6c9a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Differentiation Syndrome <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>QTc Interval Prolongation <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241119"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥ 20%) including laboratory abnormalities, are hemorrhage, nausea, phosphate increased, musculoskeletal pain, infection, aspartate aminotransferase increased, febrile neutropenia, alanine aminotransferase increased, parathyroid hormone intact increased, bacterial infection, diarrhea, differentiation syndrome, electrocardiogram QT prolonged, phosphate decreased, triglycerides increased, potassium decreased, decreased appetite, constipation, edema, viral infection, fatigue, and alkaline phosphatase increased. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Syndax Pharmaceuticals, Inc., at 1-888-539-3REV or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <linkHtml href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="25bc7aa3-0a3c-428c-aef8-8437d1d72c31"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Relapsed or Refractory Acute Leukemia with KMT2A translocation</content>
                        </paragraph>
                        <paragraph>The safety of REVUFORJ reflects exposure in 135 patients (104 adult and 31 pediatric patients) with relapsed or refractory (R/R) acute leukemia with KMT2A translocation treated with REVUFORJ at a dose approximately equivalent to 160 mg in adults orally twice daily with a strong CYP3A4 inhibitor <content styleCode="italics">[see </content>
                           <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>
                           <content styleCode="italics">]. </content>The median duration of exposure to REVUFORJ was 2.3 months (range &lt; 1 to 23 months), and 3% of patients were exposed for more than 6 months.</paragraph>
                        <paragraph>Fatal adverse reactions occurred in 4 (3%) patients who received REVUFORJ, including 2 with differentiation syndrome, 1 with hemorrhage, and 1 with sudden death. Serious adverse reactions were reported in 99 (73%) patients. The most frequent serious adverse reactions (≥ 5%) were infection (24%), febrile neutropenia (19%), bacterial infection (17%), differentiation syndrome (12%), hemorrhage (9%), and thrombosis (5%).</paragraph>
                        <paragraph>Adverse reactions leading to dose interruption occurred in 42% of patients. The most common adverse reactions (≥ 5%) leading to dose interruption were electrocardiogram QT prolonged, febrile neutropenia, differentiation syndrome, infection, hypokalemia, and nausea. Adverse reactions leading to dose reduction occurred in 10% of patients who received REVUFORJ. Adverse reactions leading to a dose reduction (&gt; 1%) included electrocardiogram QT prolonged. Adverse reactions leading to permanent discontinuation occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation (&gt; 1%) included infection and respiratory failure.</paragraph>
                        <paragraph>The most common (≥ 20%) adverse reactions were hemorrhage, nausea, phosphate increased, musculoskeletal pain, infection, aspartate aminotransferase increased, febrile neutropenia, alanine aminotransferase increased, parathyroid hormone intact increased, bacterial infection, diarrhea, differentiation syndrome, electrocardiogram QT prolonged, phosphate decreased, triglycerides increased, potassium decreased, decreased appetite, constipation, edema, viral infection, fatigue, and alkaline phosphatase increased.</paragraph>
                        <paragraph>The common adverse reactions are summarised in Table 7.</paragraph>
                        <paragraph/>
                        <table width="90%">
                           <caption> Table 7. Adverse Reactions Reported in ≥ 20% (Any Grade) or ≥ 5% (Grade 3 or 4) in Patients with R/R Acute Leukemia with KMT2A Translocation</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3"> # Includes the following fatal adverse reactions: DS (n=2); hemorrhage (n=1)<br/>a – Includes epistaxis, contusion, petechiae, gingival bleeding, haematuria, mouth hemorrhage, hematoma, hemoptysis,<br/>hemorrhoidal hemorrhage, subdural hematoma, vaginal hemorrhage, catheter site hemorrhage, conjunctival hemorrhage,<br/>ecchymosis, hemorrhage intracranial, anal hemorrhage, brain stem hemorrhage, eye hematoma, gastrointestinal hemorrhage, genital contusion, hematochezia, injection site hematoma, lower gastrointestinal hemorrhage, melena, mucosal hemorrhage, oral contusion, pulmonary, upper gastrointestinal hemorrhage, vitreous hemorrhage.<br/>b – Includes disseminated intravascular coagulation, pulmonary embolism, cerebrovascular accident, deep vein thrombosis,<br/>embolism, hemorrhoids thrombosed, medical device site thrombosis, renal infarct, superficial vein thrombosis, thrombosis,<br/>transient ischemic attack.<br/>c – Includes nausea, and vomiting.<br/>d – Includes diarrhea, colitis, neutropenic colitis.<br/>e – Includes back pain, arthralgia, pain in extremity, neck pain, myalgia, musculoskeletal chest pain, myositis, flank pain,<br/>musculoskeletal discomfort, musculoskeletal pain.<br/>f – Includes sepsis, pneumonia, urinary tract infection, septic shock, sinusitis, upper respiratory tract infection, device related infection, skin infection, acute sinusitis, enterocolitis infectious, perirectal abscess, rectal abscess, rhinitis, abscess limb, appendicitis, bronchitis, conjunctivitis, endocarditis, epididymitis, eye infection, gastroenteritis, neutropenic sepsis, osteomyelitis, rash pustular, retinitis, shock, sialadenitis, tooth abscess, tooth infection, vascular device infection.<br/>g – Includes bacteremia, cellulitis, clostridium difficile infection, staphylococcal bacteremia, paronychia, clostridium test positive, enterobacter infection, enterobacter sepsis, escherichia bacteremia, alpha haemolytic streptococcal infection, bacteriuria, cellulitis staphylococcal, enterobacter bacteremia, enterococcal bacteremia, enterococcal infection, escherichia urinary tract infection, folliculitis, klebsiella infection, klebsiella sepsis, lactobacillus bacteremia, pseudomonal bacteremia.<paragraph>h – Includes COVID-19, rhinovirus infection, respiratory syncytial virus infection, cytomegalovirus infection reactivation, herpes simplex, herpes simplex reactivation, herpes zoster, COVID-19 pneumonia, coronavirus infection, cytomegalovirus infection, cytomegalovirus test positive, enterovirus infection, enterovirus test positive, Epstein-Barr virus infection, herpes simplex pharyngitis, herpes virus infection, norovirus infection, oral herpes, pneumonia cytomegaloviral.<br/>i – Includes edema peripheral, generalised edema, edema, localized edema, peripheral swelling.<br/>j – Includes fatigue and malaise.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">REVUFORJ</content>
                                    <br/>
                                    <content styleCode="bold">N = 135</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold"> Grade 3 or 4</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Hemorrhage<sup>a#</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">53</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Thrombosis<sup>b</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">10</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Gastrointestinal disorders  </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Nausea<sup>c</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">51</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Diarrhea<sup>d</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">30</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Constipation</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">23</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Musculoskeletal pain<sup>e</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">42</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Infection<sup>f</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">41</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">29</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Bacterial infection<sup>g</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">31</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">20</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Viral infection<sup>h</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">23</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Blood and lymphatic system disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Febrile neutropenia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">35</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">33</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Leukocytosis</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">8</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Neoplasms benign, malignant and unspecified (including cysts and polyps)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Differentiation syndrome<sup>#</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">29</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">13</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Investigations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Electrocardiogram QT prolonged</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">29</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">12</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                              </tr>
                              <tr align="center">
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left">Decreased appetite </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">24 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">General disorders and administration site conditions  </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Edema<sup>i</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">23</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">1</td>
                              </tr>
                              <tr align="center">
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left">Fatigue<sup>j</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">22</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in less than 20% of patients who received REVUFORJ include:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac disorders</content>: Cardiac failure, pericardial effusion, ventricular tachycardia, cardiac arrest</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine disorders</content>: Hyperparathyroidism</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye disorders</content>: Cataract</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal disorders</content>: Abdominal pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions</content>: Sudden death</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders</content>: Drug hypersensitivity</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders</content>: Hyponatremia, hyperkalemia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders</content>: Taste disorder, syncope, headache, paresthesia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal disorders</content>: Renal impairment</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous disorders</content>: Rash</paragraph>
                        <paragraph>Changes in selected post-baseline laboratory values that were observed in patients with relapsed or refractory acute leukemia with KMT2A translocation are shown in Table 8.</paragraph>
                        <table width="90%">
                           <caption>Table 8. Selected New or Worsening Laboratory Abnormalities in Patients with R/R Acute Leukemia with KMT2A translocation</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3">*The denominator used to calculate the rate varied from 73 to 135 based on the number of patients with a baseline value and at least one post baseline value.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">REVUFORJ</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Laboratory Abnormality</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grades 1-4*</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grades 3-4</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Phosphate increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">50</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">-</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Aspartate aminotransferase increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">37</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Alanine aminotransferase increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">33</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Parathyroid hormone, intact increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">33</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">-</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Phosphate decreased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">25</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">-</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Triglycerides increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">25</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Potassium decreased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">24</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Alkaline phosphatase increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">21</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Cholesterol increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">19</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Creatinine increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">19</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Calcium corrected increased</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">15</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="49eac696-3ac0-4653-83e7-4a779bb9bf08"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20241119"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Strong CYP3A4 Inhibitors: Reduce the REVUFORJ dose. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Strong or moderate CYP3A4 Inducers: Avoid concomitant use with REVUFORJ (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>QTc Prolonging Drugs: Avoid concomitant use with REVUFORJ. If concomitant use is unavoidable, monitor patients more frequently for QTc interval prolongation. (<linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="fb7f39fa-75d0-4c0c-a7fd-cb3b9a809f3b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on REVUFORJ</title>
                     <effectiveTime value="20241119"/>
                     <component>
                        <section>
                           <id root="b3125095-6bec-401a-81aa-354045826928"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong CYP3A4 Inhibitors</content>
                              </paragraph>
                              <paragraph>If concomitant use of strong CYP3A4 inhibitors is required, reduce the REVUFORJ dosage [see <linkHtml href="#S2.2">Recommended Dosage (2.2)</linkHtml>].</paragraph>
                              <paragraph>Revumenib is primarily metabolized by CYP3A4 [see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]. Concomitant use with a strong CYP3A4 inhibitor increases revumenib systemic exposure [see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>], which may increase the risk of REVUFORJ adverse reactions.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Strong or Moderate CYP3A4 Inducers</content>
                              </paragraph>
                              <paragraph>Avoid concomitant use with strong or moderate CYP3A4 inducers.</paragraph>
                              <paragraph>Revumenib is primarily metabolized by CYP3A4 [see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]. Concomitant use with a strong or moderate CYP3A4 inducer may decrease revumenib and increase M1 systemic exposure [see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>], which may reduce REVUFORJ efficacy or increase the risk of QT prolongation associated with the M1 metabolite.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Drugs that Prolong QTc Interval</content>
                              </paragraph>
                              <paragraph>Avoid concomitant use of REVUFORJ with other drugs with a known potential to prolong QTc interval. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated [see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]. Withhold REVUFORJ if the QTc interval is greater than 480 msec. Restart REVUFORJ after the QTc interval returns to less than or equal to 480 msec [see <linkHtml href="#S2.3">Dosage and Administration (2.3</linkHtml>)].</paragraph>
                              <paragraph>REVUFORJ causes QTc interval prolongation [see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]. Concomitant use of REVUFORJ with other drugs that prolong QTc interval may result in an increase in the QTc interval and adverse reactions associated with QTc interval prolongation [see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="cf9773e0-19e9-4f2e-b34e-a61e34f997ed"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Lactation: Advise not to breastfeed (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="9573c769-0cd9-44cd-b415-508a91564a94"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250417"/>
                     <component>
                        <section>
                           <id root="1d23b684-532e-45df-abeb-9965f770c068"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary </content>
                              </paragraph>
                              <paragraph>Based on findings in animals and its mechanism of action<content styleCode="italics"> [see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>, REVUFORJ can cause fetal harm when administered to a pregnant woman. There are no available data on REVUFORJ use in pregnant women to evaluate for a drug-associated risk.</paragraph>
                              <paragraph>In an animal reproduction study, oral administration of revumenib to pregnant rats during the period of organogenesis caused adverse developmental outcomes, including embryo-fetal mortality, malformations, and altered fetal growth at maternal exposures approximately 0.5 times the human exposure (AUC) at the recommended dose (see Data). Advise pregnant women of the potential risk to a fetus.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250417"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="d214ac8e-9a0e-4785-9e7e-d50355b28f5c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                           <component>
                              <section>
                                 <id root="807677d7-3ba8-434e-bdda-97737a68e457"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study, revumenib was administered once daily via oral gavage at doses of 30, 100, and 300 mg/kg/day to pregnant rats during the period of organogenesis (gestation days 6-17). Decreased maternal body weight gain and adverse embryo-fetal findings including decreases in the number of live fetuses, increases in resorptions and post-implantation loss, and decreases in fetal body weight were observed at all doses. At 300 mg/kg/day, total litter resorption and eye malformations were observed. At the dose of 30 mg/kg/day in rats, the maternal exposures (AUC) were approximately 0.5 times the human exposure at the recommended dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20241119"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="6c3809d2-50a5-41ee-862a-0d6a7d95b38a"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241111"/>
                     <component>
                        <section>
                           <id root="5bf0b193-327c-4e15-a7f0-1716202991de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of revumenib or its metabolites in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with REVUFORJ and for 1 week after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20241111"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="a18858fa-867d-405d-8e49-1538d553878c"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3  Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20250417"/>
                     <component>
                        <section>
                           <id root="e368629a-02bc-4d78-a576-c29adf8f139c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content>Based on findings in animals and its mechanism of action, REVUFORJ can cause fetal harm when administered to pregnant women [</content>
                                 <content styleCode="italics">see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>
                                 </content>
                                 <content>].</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify pregnancy status in females of reproductive potential within 7 days prior to initiating REVUFORJ.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline"/>
                                 <content styleCode="italics">Females</content>
                              </paragraph>
                              <paragraph>
                                 <content>Advise females of reproductive potential to use effective contraception during treatment with REVUFORJ and for 4 months after the last dose.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Males</content>
                              </paragraph>
                              <paragraph>Advise males of reproductive potential to use effective contraception during treatment with REVUFORJ and for 4 months after the last dose.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                                 <br/>
                                 <content styleCode="italics">Females and Males</content>
                              </paragraph>
                              <paragraph>Based on findings in animals, REVUFORJ may impair fertility. The effects on fertility were reversible [see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</paragraph>
                           </text>
                           <effectiveTime value="20250417"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="bda2f52c-8a0e-4f2a-96c9-3221a58acb0f"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content>The safety and efficacy of REVUFORJ have been established in pediatric patients 1 year and older with relapsed or refractory acute leukemia with a KMT2A translocation. Use of REVUFORJ for this indication is supported by evidence from adequate and well-controlled trials in adults and pediatric patients </content>
                           <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>] </content>
                           <content>and additional pharmacokinetic and safety data in pediatric patients </content>
                           <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and </content>
                           <content styleCode="italics">
                              <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>
                           <content>. The patients included 13 infants (age &lt; 2 years), 41 children (age 2 to &lt; 12 years) and 16 adolescents (age 12 to &lt; 17 years). The recommended dosage in patients weighing less than 40 kg is BSA-based.</content>
                        </paragraph>
                        <paragraph>
                           <content>The safety and efficacy of REVUFORJ in pediatric patients less than 1 year old have not been established.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">
                              <content>Animal Data</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content>In a repeat dose toxicity study in 6-7 week-old rats treated with revumenib at 75, 150, or 300 mg/kg/day for 13 weeks, an irreversible increase in femur growth plate closure was observed at revumenib exposures approximately 2 times the human exposure (AUC) at the recommended dose.</content>
                        </paragraph>
                        <paragraph>Based on the findings in animals, monitor bone growth and development in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="5ba9b67c-d39d-4f0f-84c4-d4edd64e16b4"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 135 patients with relapsed or refractory acute leukemia with a KMT2A translocation in clinical studies of REVUFORJ, 16 (12%) patients were 65 years of age and older and 3 (2%) patients were 75 years of age and older [see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</paragraph>
                        <paragraph>No overall differences were observed in the effectiveness of REVUFORJ between patients who were 65 years and older and younger patients [see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]. Compared to younger patients, the incidences of QTc prolongation and edema were higher in patients 65 years and older [see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="0e7a7b0a-b0bf-4aab-b223-474a74d95e21"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>REVUFORJ contains revumenib, a menin inhibitor. Revumenib is present as revumenib citrate hydrate with a chemical name of benzamide, <content styleCode="italics">N</content>-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-[1-methylethyl]-, 2-hydroxypropane-1,2,3-tricarboxylic acid, hydrate (1:1:1). The molecular formula is C<sub>32</sub>H<sub>47</sub>FN<sub>6</sub>O<sub>4</sub>S●C<sub>6</sub>H<sub>8</sub>O<sub>7</sub>●H<sub>2</sub>O with a molecular weight 840.96 g/mol.</paragraph>
                  <paragraph>Revumenib citrate hydrate is a white to faint pink solid. Revumenib citrate hydrate is soluble at pH 1.2 and 6.8, and sparingly soluble at pH 4.5.</paragraph>
                  <paragraph/>
                  <paragraph>The chemical structure is shown in Figure 1.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Chemical structure of Revumenib Citrate</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ld0431b7a-7ab4-41b9-8768-c838e9cd45e2"/>
                  </paragraph>
                  <paragraph>REVUFORJ is available as tablets for oral use. </paragraph>
                  <paragraph>Each 25 mg strength tablet contains 25 mg revumenib, equivalent to 33.4 mg revumenib citrate, and the following inactive ingredients: microcrystalline cellulose, dicalcium phosphate, crospovidone, hypromellose, sodium bicarbonate, hydrophobic colloidal silica, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and red iron oxide.</paragraph>
                  <paragraph>Each 110 mg strength tablet contains 110 mg revumenib, equivalent to 146.5 mg revumenib citrate, and the following inactive ingredients: microcrystalline cellulose, dicalcium phosphate, crospovidone, hypromellose, sodium bicarbonate, hydrophobic colloidal silica, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, red iron oxide, and yellow iron oxide.</paragraph>
                  <paragraph>Each 160 mg strength tablet contains 160 mg revumenib equivalent to 213.2 mg revumenib citrate, and the following inactive ingredients: microcrystalline cellulose, dicalcium phosphate, crospovidone, hypromellose, sodium bicarbonate, hydrophobic colloidal silica, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, red iron oxide, and FD&amp;C blue #2/indigo carmine aluminum lake.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="Ld0431b7a-7ab4-41b9-8768-c838e9cd45e2">
                     <text>Chemical Structure of Revumenib Citrate</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Chemical Structure of Revumenib Citrate.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="01b2bf96-bb63-4f24-a245-917878633e6c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241119"/>
               <component>
                  <section ID="S12.1">
                     <id root="8dd3252e-a74b-4f42-8775-70a0f4748f34"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Revumenib is a menin inhibitor and blocks the interaction of both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of KMT2A fusion proteins with menin is involved in KMT2A-rearranged (KMT2Ar) acute leukemias through activation of a leukemogenic transcriptional pathway. In nonclinical studies using cells that express KMT2A fusions, inhibition of the menin-KMT2A interaction with revumenib altered the transcription of multiple genes including differentiation markers.</paragraph>
                        <paragraph>In nonclinical in vitro and in vivo studies, revumenib demonstrated antiproliferative and antitumor activity in leukemia cells harboring KMT2A fusion proteins.</paragraph>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="7ee5519b-6a0c-4691-ab9b-226e06966165"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20241119"/>
                     <component>
                        <section>
                           <id root="f6ebfc83-df9a-43c9-bbe4-8df829567305"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content>Revumenib exposure-response relationships have not been fully characterized and the time course of pharmacodynamic response is unknown.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">
                                    <content>Cardiac Electrophysiology</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content>The effect of REVUFORJ on the QTc interval was evaluated across a dose range of 113 mg to 339 mg twice daily (1.2 times the highest adult approved recommended dosage) with and without strong CYP3A4 inhibitors in patients with relapsed or refractory acute leukemia with KMT2Ar.</content>
                              </paragraph>
                              <paragraph>
                                 <content>The increase in QTc interval was concentration dependent with an increase in QTc predicted to be 27 msec (upper bound of 90% confidence interval: 30 msec) at the mean steady-state maximum concentration (C<sub>max</sub>) observed in patients at the highest approved recommended dosage without CYP3A4 inhibitors. The increase in QTc interval was predicted to be 19 msec (upper bound of 90% confidence interval: 22 msec) at steady-state C<sub>max</sub> after administration of 163 mg twice daily with strong CYP3A4 inhibitors</content>
                                 <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                                 <content>.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="0358230b-ea83-45e6-b530-664c85d9c06e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of revumenib were characterized in patients with relapsed or refractory acute leukemia following single and multiple oral administration of revumenib with or without strong CYP3A4 inhibitors. Steady-state pharmacokinetic parameters are presented as geometric mean [coefficient of variation (%CV)] unless otherwise specified.</paragraph>
                        <table width="80%">
                           <caption> Table 9. Revumenib Pharmacokinetics in Patients with Relapsed or Refractory Acute Leukemia</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3">Abbreviations: C<sub>max</sub> = maximum plasma concentration; AUC = area under the time concentration curve; T<sub>max</sub> = time to peak concentration<br/>
                                    <sup>a</sup> - 1.02 times the highest adult approved recommended dosages<br/>
                                    <sup>b</sup> - Steady-state<br/>
                                    <sup>c</sup> - Dosage range of 113 mg to 339 mg (1.26 times the highest adult approved recommended dosage)<br/>
                                    <sup>d</sup> - Approximately 400-500 calories, 25% of calories from fat<br/>
                                    <sup>e</sup> - Independent of concentration<br/>
                                    <sup>f</sup> - M1 contributes to revumenib’s clinically significant effects on QTc [see <content styleCode="italics">
                                       <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>
                                    </content> and <content styleCode="italics">
                                       <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>
                                    </content>] but does not contribute to its efficacy at the approved recommended dosage<br/>
                                    <sup>g</sup> - A single dose of radiolabeled revumenib 276 mg (1.02 times the highest adult approved recommended dosage) to adult patients with relapsed/refractory acute leukemia</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" rowspan="2">
                                    <paragraph>
                                       <content styleCode="bold">Parameter</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" colspan="2">
                                    <paragraph>
                                       <content styleCode="bold">Dosage</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">163 mg twice daily </content>
                                    <content styleCode="bold">(with strong CYP3A4 inhibitors)<sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <paragraph>
                                       <content styleCode="bold">276 mg twice daily </content>
                                       <content styleCode="bold">(without strong CYP3A4 inhibitors)<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">General Information   </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="italics">Exposure<sup>b</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">C<sub>max</sub> (ng/mL)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">3220 (34%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2052 (79%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">AUC<sub>0-12h</sub> (ng•h/mL)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">22,610 (50%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">10,150 (69%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dose Proportionality<sup>c</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">Dose proportional increases in C<sub>max</sub> and AUC<sub>0-12h</sub>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"> Time to Steady-State</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">2-3 days </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Accumulation<sup>b</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">2-fold </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Absorption</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">T<sub>max</sub> Median (range) hours</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">2 (0-6)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">1 (0.5-4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="italics">Effect of Food</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Low fat meal<sup>d</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">No clinically significant differences in revumenib pharmacokinetics observed (C<sub>max</sub> and AUC decreased by 27% and 12% respectively) </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Distribution</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Apparent Volume of <br/>Distribution<sup>b</sup> (L)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center">78 (50%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Protein Binding<sup>e</sup>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center">90%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Blood to plasma ratio</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" align="center">0.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Elimination</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Half-Life<sup>b</sup> (hours)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">7.5 (57%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">3.6 (36%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Apparent Clearance<sup>b</sup> (L/h)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">7 (51%)</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">27 (69%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="italics">Metabolism</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Primary Pathway</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">CYP3A4 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Active Metabolite</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">M1<sup>f</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="italics">Excretion</content>
                                    <sup>g</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Feces</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">Approximately 49% (7% unchanged)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Urine</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2">Approximately 27% (7% unchanged) </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241119"/>
                     <component>
                        <section>
                           <id root="824b15dd-3030-4bb3-b60f-98ff111f6b93"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of revumenib were observed based on age (1 to 82 years), race (71% White, 8% Asian, 8% Black), sex, mild to moderate (CLcr 30 to 89 mL/min) renal impairment, and mild (total bilirubin ≤ upper limit of normal [ULN] and AST &gt; ULN or total bilirubin &gt; 1 to 1.5 × ULN and any AST) or moderate (total bilirubin &gt; 1.5 to 3 × ULN and any AST) hepatic impairment. The effect of severe renal impairment (CLcr less than 30 mL/min), end-stage renal disease (CLcr less than 15 mL/min), or severe (total bilirubin &gt; 3 × ULN and any AST) hepatic impairment is unknown.</paragraph>
                              <paragraph>Body weight (8-146 kg) has a significant effect on the pharmacokinetics of revumenib, with higher revumenib exposures in patients with lower body weight (less than 40 kg). This supports the use of BSA-based dosage in patients weighing less than 40 kg.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Pediatric Patients</content>
                              </paragraph>
                              <paragraph>Revumenib geometric mean (CV%) steady-state C<sub>max</sub> was 3137 (39%) ng/mL and AUC<sub>0-tau</sub> was 14,630 (55%) ng·hr/mL following 95 mg/m<sup>2</sup> twice daily (approximately 1.02 times the highest approved recommended adult dosage) with strong CYP3A4 inhibitors.</paragraph>
                              <paragraph>Revumenib predicted geometric mean (%CV) steady-state C<sub>max</sub> was 1597 (70%) ng/mL and AUC<sub>0-tau</sub> was 12,570 (56%) ng·hr/mL following 160 mg/m<sup>2</sup> twice daily (approximately 1.02 times the highest approved recommended adult dosage) without strong CYP3A4 inhibitors.</paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cd38a2a9-78bc-4585-a40a-575aa3bf46b2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                           <component>
                              <section>
                                 <id root="bf67461b-a68f-41f8-840c-60f8a5e8e42a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Clinical Studies</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">
                                          <content styleCode="underline">Strong CYP3A4 Inhibitors</content>
                                       </content>: Revumenib AUC and C<sub>max</sub> is increased by 2-fold following concomitant use of multiple doses of revumenib with certain azole antifungals that are strong CYP3A4 inhibitors (i.e., posaconazole, itraconazole, and voriconazole). Similarly, revumenib AUC and C<sub>max</sub> is increased by 2.5-fold following concomitant use of multiple doses of revumenib with cobicistat (strong CYP3A4 inhibitor).</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">
                                          <content styleCode="underline">Strong and Moderate CYP3A4 Inducers</content>
                                       </content>: Revumenib exposure is expected to decrease and M1 exposure is expected to increase with strong and moderate CYP3A4 inducers.</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">
                                          <content styleCode="underline">Other Drugs</content>
                                       </content>: No clinically significant differences in revumenib pharmacokinetics were observed when used concomitantly with fluconazole (moderate CYP3A4 inhibitor), isavuconazole (moderate CYP3A4 inhibitor).</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="underline">
                                          <content styleCode="italics">Cytochrome P450 (CYP) Enzymes</content>
                                       </content>: Revumenib inhibits CYP3A4, but does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1.</paragraph>
                                    <paragraph>
                                       <content>Revumenib does not induce CYP1A2, CYP2B6, and CYP3A4.</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="underline">
                                          <content styleCode="italics">Transporter Systems</content>
                                       </content>: Revumenib is a substrate of OCT1, OCT2, OAT1, OAT3, and MATE1, but is not a substrate of P-gp, BCRP, OATP1B1, OATP1B3, MATE2-K, or BSEP. M1 is a substrate of OATP1B1, but is not a substrate of P-gp, BCRP, OCT2, OAT1, OAT3, OATP1B3, MATE1, or MATE2-K.</paragraph>
                                    <paragraph>Revumenib inhibits MATE1, but does not inhibit P-gp, BCRP, OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3, BSEP, and MATE2-K. M1 inhibits MATE1, but does not inhibit OAT1, OAT3, OCT2, OATP1B1, OATP1B3, and MATE2-K.</paragraph>
                                 </text>
                                 <effectiveTime value="20241119"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="f27bb8b6-0df2-4dac-8d48-a93c85f61cbb"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241119"/>
               <component>
                  <section ID="S13.1">
                     <id root="00f96385-0c3e-4ed8-8f49-be2b351bbce3"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with revumenib. In a repeat dose toxicity study in rats treated with revumenib for 13 weeks, lymphoma was observed in multiple organs in one animal.</paragraph>
                        <paragraph>Revumenib was not genotoxic in an in vitro bacterial reverse mutation (Ames) assay, an in vitro micronucleus assay in human peripheral blood lymphocytes, or an in vivo rat peripheral blood reticulocyte micronucleus assay.</paragraph>
                        <paragraph>Fertility studies in animals have not been conducted with revumenib.</paragraph>
                        <paragraph>In a repeat dose toxicity study in dogs treated with revumenib at 12.5, 25 or 40 mg/kg/day for 13 weeks, microscopic findings in the testes and epididymis consisted of depletion of germ cells and decreased sperm at ≥12.5 mg/kg/day. In females, microscopic changes of atrophy in the mammary glands, uterus, and vagina and decreased number of corpora lutea in the ovaries were observed at ≥12.5 mg/kg/day. At the end of the 13-week recovery period, the findings in the female reproductive organs were reversed at all doses, and the testicular and epididymal effects were reversed at 12.5 mg/kg/day. At the dose of 12.5 mg/kg/day in dogs, exposures (AUC) were approximately 1.3 times the human exposure (AUC) at the recommended dose.</paragraph>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="54908a66-8d67-48f2-8263-36393c10d998"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In a repeat dose toxicity study in dogs treated with revumenib at 12.5, 25, or 40 mg/kg/day for 13 weeks, microscopic findings of nerve fiber degeneration in the brain, sciatic nerves, and spinal cord segments were observed at ≥ 12.5 mg/kg/day and were not reversed at the end of a 13-week recovery period.</paragraph>
                        <paragraph>In a repeat dose toxicity study in rats treated with revumenib at 75, 150, 300 mg/kg/day for 13 weeks, dose dependent ocular findings of lens opacities were observed at ≥ 75 mg/kg/day; the findings progressed during the dosing and recovery periods and were not reversed.</paragraph>
                        <paragraph>Hyperplasia was observed in multiple organs including the testes, mammary gland, uterus, pancreas, and kidney in rats treated at ≥ 75 mg/kg/day for up to 13 weeks. The findings were irreversible in the testes, mammary gland, and pancreas. Revumenib exposures at 75 mg/kg/day in rats are approximately 2 times the human exposure (AUC) at the recommended dose.</paragraph>
                     </text>
                     <effectiveTime value="20241111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="2d75adb5-e936-42ef-8af9-2a4556109939"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250422"/>
               <component>
                  <section ID="S14.1">
                     <id root="7b46cab4-db62-45ce-87d7-c1ca3039bc1a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Relapsed or Refractory Acute Leukemia with a KMT2A Translocation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">SNDX-5613-0700</content>
                        </paragraph>
                        <paragraph>The efficacy of REVUFORJ was evaluated in a single-arm cohort of an open-label, multicenter trial (SNDX-5613-0700, <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT04065399">NCT04065399</linkHtml>; AUGMENT-101) in adult and pediatric patients at least 30 days old with relapsed or refractory (R/R) acute leukemia with a KMT2A translocation. Patients with an 11q23 partial tandem duplication were excluded. Eligibility required a QTcF &lt; 450 msec at study baseline. Treatment consisted of REVUFORJ at a dose approximately equivalent to 160 mg in adults orally twice daily with a strong CYP3A4 inhibitor until disease progression, unacceptable toxicity, failure to achieve morphological leukemia-free state by 4 cycles of treatment, or hematopoietic stem cell transplantation (HSCT).</paragraph>
                        <paragraph>The baseline demographic and disease characteristics of the 104 treated patients are shown in Table 10. Twenty-four (23%) patients underwent HSCT following treatment with REVUFORJ.</paragraph>
                        <table width="70%">
                           <caption>Table 10. Baseline Demographic and Disease Characteristics in Patients with Relapsed or Refractory Acute Leukemia with KMT2A translocation (Study SNDX-5613-0700)</caption>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="2" align="left">1. One patient did not have a translocation type reported.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="bold">Demographic and Disease Characteristics  </content>
                                 </td>
                                 <td styleCode="Lrule Rrule" align="center">
                                    <paragraph>
                                       <content styleCode="bold">REVUFORJ</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 104</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="bold">Demographics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Median Age (years) (Range)</td>
                                 <td styleCode="Rrule" align="center">37 (1, 79)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">Age, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  &lt; 17 years old</td>
                                 <td styleCode="Rrule" align="center">25 (24)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  ≥ 17 years old</td>
                                 <td styleCode="Rrule" align="center">79 (76)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">Sex, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Male</td>
                                 <td styleCode="Rrule" align="center">37 (36)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Female</td>
                                 <td styleCode="Rrule" align="center">67 (64)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">Race, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Black or African American</td>
                                 <td styleCode="Rrule" align="center">8 (8)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Asian</td>
                                 <td styleCode="Rrule" align="center">10 (10)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  White</td>
                                 <td styleCode="Rrule" align="center">75 (72)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Multiple</td>
                                 <td styleCode="Rrule" align="center">1 (1)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Unknown</td>
                                 <td styleCode="Rrule" align="center">10 (10)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">Ethnicity, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Hispanic or Latino</td>
                                 <td styleCode="Rrule" align="center">23 (22)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Not Hispanic or Latino</td>
                                 <td styleCode="Rrule" align="center">76 (73)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Unknown</td>
                                 <td styleCode="Rrule" align="center">5 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="bold">Disease Characteristics</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">Leukemia morphological type, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Acute myeloid leukemia (AML)</td>
                                 <td styleCode="Rrule" align="center">86 (83)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Acute lymphoblastic leukemia (ALL)</td>
                                 <td styleCode="Rrule" align="center">16 (15)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Mixed phenotype acute leukemia (MPAL)</td>
                                 <td styleCode="Rrule" align="center">2 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Translocations<sup>1</sup>, n (%)</td>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   t(9;11)</td>
                                 <td styleCode="Rrule" align="center">23 (22)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <paragraph>   t(11;19)</paragraph>
                                 </td>
                                 <td styleCode="Rrule" align="center">20 (19)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   t(6;11)</td>
                                 <td styleCode="Rrule" align="center">10 (10)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   t(10;11)</td>
                                 <td styleCode="Rrule" align="center">10 (10)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   t(4;11)</td>
                                 <td styleCode="Rrule" align="center">7 (7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   t(1;11)</td>
                                 <td styleCode="Rrule" align="center">3 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <paragraph>   t(11;17)</paragraph>
                                 </td>
                                 <td styleCode="Rrule" align="center">2 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   t(11;22)</td>
                                 <td styleCode="Rrule" align="center">2 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   t(11;16)</td>
                                 <td styleCode="Rrule" align="center">1 (1)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   KMT2A fusion partner unknown  </td>
                                 <td styleCode="Rrule" align="center">26 (25)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Disease status, n (%)</td>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Primary refractory</td>
                                 <td styleCode="Rrule" align="center">22 (21)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Untreated relapse</td>
                                 <td styleCode="Rrule" align="center">21 (20)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Refractory relapse</td>
                                 <td styleCode="Rrule" align="center">61 (59)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">Prior treatment</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Number of prior regimens, median (range)</td>
                                 <td styleCode="Rrule" align="center">2 (1, 11)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Prior stem cell transplantation, n (%)</td>
                                 <td styleCode="Rrule" align="center">46 (44)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">Number of prior relapses, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   0</td>
                                 <td styleCode="Lrule Rrule" align="center">22 (21)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   1</td>
                                 <td styleCode="Rrule" align="center">55 (53)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   2</td>
                                 <td styleCode="Rrule" align="center">20 (19)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">   ≥3</td>
                                 <td styleCode="Rrule" align="center">7 (7)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Efficacy was established on the basis of the rate of complete remission (CR) plus CR with partial hematologic recovery (CRh), the duration of CR+CRh, and the rate of conversion from transfusion dependence to transfusion independence. The median follow-up was 5.73 months (range, 0.3 to 28.9 months). The efficacy results are shown in Table 11. On subgroup analysis, CR+CRh was achieved by 18/86 (21%) of patients with AML, 3/16 (19%) of patients with ALL, and 1/2 (50%) of patients with MPAL.</paragraph>
                        <table width="70%">
                           <caption>Table 11. Efficacy Results in Patients with Relapsed or Refractory Acute Leukemia with KMT2A translocation (Study SNDX-5613-0700)</caption>
                           <colgroup>
                              <col width="40%" align="left" valign="top"/>
                              <col width="60%" align="center" valign="top"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="2" align="left">CI: confidence interval; NE = not estimable; DOCR = duration of CR; DOCRh = duration of CRh.<br/>1. CR is defined as bone marrow blasts &lt;5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 × 10<sup>9</sup>/L and platelet count ≥100 × 10<sup>9</sup>/L.<br/>2. CRh is defined as bone marrow blasts &lt;5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; residual neutropenia (&gt;0.5 × 10<sup>9</sup>/L) and thrombocytopenia (&gt;50 × 10<sup>9</sup>/L), but the count recovery criteria for CR are not met.<br/>3. Duration of CR+CRh is defined as the time from first CR or CRh to the first documented relapse or death, whichever occurs first.<br/>4. Duration of CR is defined as the time from first CR to the first documented relapse or death, whichever occurs first.<br/>5. Duration of CRh is defined as the time from first CRh to the first documented relapse or death, whichever occurs first.<br/>6. The 95% CI of the response rate is derived using the exact method based on binomial distribution. The median of the response duration is derived using Kaplan-Meier method.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="left">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">REVUFORJ N=104</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">CR<sup>1</sup>+CRh<sup>2</sup> n (%)</td>
                                 <td styleCode="Rrule" align="center">22 (21.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">  95% CI</td>
                                 <td styleCode="Rrule" align="center">(13.8, 30.3)<sup>6</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Median DOCR+CRh<sup>3</sup> (months)</td>
                                 <td styleCode="Rrule" align="center">6.4<sup>6</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  95% CI</td>
                                 <td styleCode="Rrule" align="center">(2.7, NE)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">CR n (%)</td>
                                 <td styleCode="Rrule" align="center">13 (12.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">  95% CI</td>
                                 <td styleCode="Rrule" align="center">(6.8, 20.4)<sup>6</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Median DOCR<sup>4</sup> (months)</td>
                                 <td styleCode="Rrule" align="center">4.3<sup>6</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  95% CI</td>
                                 <td styleCode="Rrule" align="center">(1.0, NE)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">CRh n (%)</td>
                                 <td styleCode="Rrule" align="center">9 (8.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">  95% CI</td>
                                 <td styleCode="Rrule" align="center">(4.0, 15.8)<sup>6</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Median DOCRh<sup>5</sup> (months)</td>
                                 <td styleCode="Rrule" align="center">6.4<sup>6</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">  95% CI</td>
                                 <td styleCode="Rrule" align="center">(1.9, NE)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Of the 22 patients who achieved a CR or CRh, the median time to CR or CRh was 1.9 months (range: 0.9, 5.6 months).<br/>Among the 83 patients who were dependent on red blood cell (RBC) and/or platelet transfusions at baseline, 12 (14%) became independent of RBC and platelet transfusions during any 56-day post-baseline period. Of the 21 patients who were independent of both RBC and platelet transfusions at baseline, 10 (48%) remained transfusion independent during any 56-day post-baseline period.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="eaa7439a-20f4-4adf-88bb-8aa9f51800b2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250422"/>
               <component>
                  <section>
                     <id root="ecd47520-d6c7-42c7-bb0b-560c2ac16229"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>25 mg: Pink modified oval film-coated tablet debossed with “S” on one side and “25” on the other side.</paragraph>
                        <list listType="unordered">
                           <item>30-count bottles with a desiccant and child resistant closure (NDC 73555-500-00)</item>
                        </list>
                        <paragraph>110 mg: Beige modified oval film-coated tablet debossed with “S” on one side and “110” on the other side.</paragraph>
                        <list listType="unordered">
                           <item>30-count bottles with a desiccant and child resistant closure (NDC 73555-501-00)</item>
                        </list>
                        <paragraph>160 mg: Purple modified oval film-coated tablet debossed with “S” on one side and “160” on the other side.</paragraph>
                        <list listType="unordered">
                           <item>30-count bottles with a desiccant and child resistant closure (NDC 73555-502-00)</item>
                        </list>
                     </text>
                     <effectiveTime value="20250422"/>
                     <component>
                        <section>
                           <id root="a1b3d7ea-17f9-419a-adb2-29c790df411a"/>
                           <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                           <text>
                              <paragraph>Store tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                              <paragraph>Keep in original container until dispensed.</paragraph>
                           </text>
                           <effectiveTime value="20250422"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="76e333ed-0eae-47e1-8a13-a450b109474e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide) and Instructions for Use.</paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <section>
                     <id root="d68e4938-644b-49f2-b88f-40c22b4d1da3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Differentiation Syndrome</content>
                        </paragraph>
                        <paragraph>Advise patients of the risks of developing differentiation syndrome as early as 1 day after the start of therapy and during treatment. Ask patients to immediately report any symptoms suggestive of differentiation syndrome, such as fever, cough or difficulty breathing, rash, low blood pressure, rapid weight gain, swelling of their arms or legs, or decreased urinary output, to their healthcare provider for further evaluation<content styleCode="italics"> [see <linkHtml href="#BOX">Boxed Warning</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d0dc52f2-b4c4-40b9-9e62-088be2388a2b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Prolonged QT Interval</content>
                        </paragraph>
                        <paragraph>Advise patients to consult their healthcare provider immediately if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia. Advise patients with a history of hypokalemia or hypomagnesemia of the importance of monitoring their electrolytes<content styleCode="italics"> [see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3b4ac913-a2ca-4197-89ba-4ac640e99072"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider of a known or suspected pregnancy [<content styleCode="italics">see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with REVUFORJ and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with REVUFORJ and for 4 months after the last dose [<content styleCode="italics">see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20241119"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="56d6c5dc-ab5f-487f-a195-a6028b0c70a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with REVUFORJ and for 1 week after the last dose<content styleCode="italics"> [see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241111"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e387e921-5a01-4a97-b7fb-46f969394a48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Advise females and males of reproductive potential of the potential for impaired fertility from REVUFORJ [see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>, <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20241111"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9e211ead-4ae7-4042-a668-43938fd27750"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare providers of all concomitant products, including over-the counter products and supplements<content styleCode="italics"> [see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241111"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="41083ecf-0bac-4df0-8c7a-8d66faf9c6b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosing Instructions</content>
                        </paragraph>
                        <paragraph>Advise patients to swallow tablets whole with a cup of water and not to cut or chew tablets. If patients are unable to swallow the tablets, they may be crushed and dispersed in water [see <content styleCode="italics">Instructions for Use</content>]. Instruct patients that, if they miss a dose of REVUFORJ, to take it as soon as possible on the same day, and at least 12 hours prior to the next scheduled dose, and return to the normal schedule the following day [see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="583cf86d-64ed-41b1-9f39-c3b40e641e76"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for<br/>
                     <content styleCode="italics">Syndax Pharmaceuticals, Inc., New York, NY 10017</content>
                  </paragraph>
                  <paragraph>REVUFORJ ® is a registered trademark of Syndax Pharmaceuticals, Inc.<br/>© 2025 Syndax Pharmaceuticals, Inc.</paragraph>
                  <paragraph/>
                  <paragraph>218944-SYND-USPI-002</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250422"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3e44766f-1e1c-4f77-bc81-1e5765dd2fed"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <colgroup>
                        <col width="3%" align="left" valign="top"/>
                        <col width="47%" align="left" valign="top"/>
                        <col width="50%" align="left" valign="top"/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td colspan="2" align="left">
                              <content styleCode="SageEmphasis0">This Medication Guide has been approved by the U.S. Food and Drug Administration</content>
                           </td>
                           <td align="right">
                              <content styleCode="SageEmphasis0">Revised: 04/2025</content>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule First">
                           <td styleCode="Lrule Rrule" colspan="3" align="center">
                              <content styleCode="bold">Medication Guide </content>
                              <content styleCode="bold">REVUFORJ (REV-you-forge)</content>
                              <br/>(revumenib)<br/>tablets, for oral use</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph ID="whatis">
                                 <content styleCode="bold">What is the most important information I should know about REVUFORJ?<br/>REVUFORJ may cause serious side effects including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">differentiation syndrome. </content>Differentiation syndrome is a serious, but common condition that affects your blood cells which may be life threatening or lead to death if not treated. Differentiation syndrome has happened as early as 3 days and up to 41 days after starting REVUFORJ. Tell any healthcare provider caring for you that you are taking a medicine that can cause differentiation syndrome. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome during treatment with REVUFORJ: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td align="left">
                              <list listType="unordered" styleCode="Circle">
                                 <item>fever</item>
                                 <item>cough</item>
                                 <item>shortness of breath</item>
                                 <item>severe headache</item>
                                 <item>confusion</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="Circle">
                                 <item>dizziness or lightheadedness</item>
                                 <item>fast weight gain</item>
                                 <item>swelling of arms, legs, neck, groin, or underarm area</item>
                                 <item>decreased urination</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td styleCode="Rrule" colspan="2" align="left">
                              <paragraph>If you develop any of these symptoms of differentiation syndrome, your healthcare provider may start you on a medicine given through a vein (intravenous) called corticosteroids and may monitor you in the hospital.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">See <content styleCode="bold">"What are the possible side effects of REVUFORJ?"</content> for more information about side effects.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <content styleCode="bold">What is REVUFORJ?</content>
                              <br/>REVUFORJ is a prescription medicine used to treat adults and children 1 year and older with acute leukemia with a lysine methyltransferase 2A gene translocation (KMT2A) whose disease has come back or has not improved after previous treatment(s).<br/>Your healthcare provider will perform a test to make sure that REVUFORJ is right for you.<br/>It is not known if REVUFORJ is safe and effective in children less than 1 year of age.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph styleCode="First SageBodyText">
                                 <content styleCode="SageEmphasis0">
                                    <content styleCode="bold">Before taking REVUFORJ, t</content>
                                 </content>
                                 <content styleCode="bold">ell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>have any heart problems, including a condition called long QT syndrome.</item>
                                 <item>have been told you have low blood levels of potassium or magnesium.</item>
                                 <item>are pregnant or plan to become pregnant. REVUFORJ can harm your unborn baby.<br/>o   <content styleCode="SageEmphasis0">Your healthcare provider will perform a pregnancy test within 7 days before you start treatment with REVUFORJ. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with REVUFORJ.<br/>o   <content styleCode="bold">Females</content> who are able to become pregnant should use effective birth control (contraception) during treatment with REVUFORJ and for 4 months after the last dose of REVUFORJ.</content>
                                    <br/>o   <content styleCode="bold">Males</content> who have female partners who are able to become pregnant should use effective birth control during treatment with REVUFORJ and for 4 months after the last dose of REVUFORJ.<br/>
                                    <content styleCode="SageEmphasis0">o   Talk to your healthcare provider about birth control methods you can use during this time.</content>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if <content styleCode="SageEmphasis0">REVUFORJ passes into your breast milk. <content styleCode="bold">Do not</content> breastfeed during your treatment with REVUFORJ or for 1 week after your last dose of REVUFORJ.</content>
                                 </item>
                              </list>
                              <paragraph styleCode="SageBodyText">
                                 <content styleCode="bold">Tell your healthcare provider about any other medications you take, </content>
                                 <content styleCode="bold">including </content>prescription and over‑the‑counter medicines, vitamins, and herbal supplements.<br/>REVUFORJ and other medicines may affect each other causing side effects.</paragraph>
                              <content styleCode="SageEmphasis0">Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph styleCode="First SageBodyText">
                                 <content styleCode="SageEmphasis0">
                                    <content styleCode="bold">How should I take REVUFORJ?</content>
                                 </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="SageEmphasis0">
                                       <content styleCode="bold">Take REVUFORJ exactly as your healthcare provider tells you to</content>
                                    </content>
                                    <content styleCode="SageEmphasis0">. <content styleCode="bold">Do not</content> change your dose or stop taking REVUFORJ unless your healthcare provider tells you to.</content>
                                 </item>
                                 <item>REVUFORJ tablets come in different strengths. Each strength is a different color. Your healthcare provider may prescribe more than 1 strength of REVUFORJ tablets for you, so it is important that you understand how to take your medicine the right way. Be sure that you understand exactly how many tablets you need to take, and what strengths to take.</item>
                                 <item>Take REVUFORJ 2 times a day at about the same time each day about 12 hours apart.</item>
                                 <item>
                                    <paragraph styleCode="First SageBodyText">REVUFORJ can be taken fasted or with a low-fat meal.</paragraph>
                                 </item>
                                 <item>
                                    <paragraph styleCode="First SageBodyText">
                                       <content styleCode="SageEmphasis0">Swallow REVUFORJ tablets whole with a cup of water. If you are unable to swallow tablets, crush the tablets and break them apart in water. See the <content styleCode="bold">Instructions for Use</content> for detailed instructions on how to prepare and give REVUFORJ tablets. <content styleCode="bold">Do not</content> cut or chew tablets.</content>
                                    </paragraph>
                                 </item>
                                 <item>
                                    <paragraph styleCode="First SageBodyText">If you miss a dose of REVUFORJ or did not take it at the usual time, take your dose as soon as possible and at least 12 hours before your next dose. <content styleCode="bold">Do not</content> take 2 doses within 12 hours. Return to your normal scheduled dose the following day.</paragraph>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph styleCode="First SageBodyText">
                                 <content styleCode="SageEmphasis0">
                                    <content styleCode="bold">What are the possible side effects of REVUFORJ?</content>
                                 </content>
                              </paragraph>
                              <paragraph styleCode="SageBodyText">
                                 <content styleCode="SageEmphasis0">
                                    <content styleCode="bold">REVUFORJ may cause serious side effects including:</content>
                                 </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="SageEmphasis0">see “<content styleCode="bold">What is the most important information I should know about REVUFORJ?</content>”</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">changes in electrical activity of your heart called QT prolongation.</content>
                                    <content styleCode="SageEmphasis0"> QT prolongation is a serious, but common side effect that can cause irregular heartbeats that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with REVUFORJ. Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or if you feel your heart beating irregularly or fast during treatment with REVUFORJ. </content>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of REVUFORJ include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left"/>
                           <td align="left">
                              <list listType="unordered">
                                 <item>bleeding (hemorrhage)</item>
                                 <item>nausea and vomiting</item>
                                 <item>muscle pain</item>
                                 <item>infections, including bacterial and viral infections</item>
                                 <item>low white blood cell counts with fever</item>
                                 <item>diarrhea</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered">
                                 <item>changes in liver function tests</item>
                                 <item>swelling in the arms and legs</item>
                                 <item>decreased appetite</item>
                                 <item>constipation</item>
                                 <item>tiredness</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph styleCode="First SageListBullet">
                                 <content styleCode="SageEmphasis0">Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with REVUFORJ if you develop certain side effects.</content>
                              </paragraph>
                              <paragraph styleCode="SageListBullet">
                                 <content styleCode="SageEmphasis0">REVUFORJ may cause fertility problems in females and males. Talk to your healthcare provider if this is a concern for you. </content>
                              </paragraph>
                              <paragraph styleCode="SageListBullet">
                                 <content styleCode="SageEmphasis0">These are not all possible side effects of REVUFORJ.</content>
                              </paragraph>
                              <content styleCode="SageEmphasis0">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph styleCode="First SageBodyText">
                                 <content styleCode="SageEmphasis0">
                                    <content styleCode="bold">How should I store REVUFORJ?</content>
                                 </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Store REVUFORJ at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Keep the tablets in the bottle that it comes in until you are ready to take it.</item>
                                 <item>The REVUFORJ bottle has a drying agent (desiccant) and child resistant closure.</item>
                              </list>
                              <content styleCode="SageEmphasis0">
                                 <content styleCode="bold">Keep REVUFORJ and all medicines out of reach of children.</content>
                              </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph styleCode="First SageBodyText">
                                 <content styleCode="SageEmphasis0">
                                    <content styleCode="bold">General information about the safe and effective use of REVUFORJ.</content>
                                 </content>
                              </paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use REVUFORJ for a condition for which it is not prescribed. Do not give REVUFORJ to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or health professionals for information about REVUFORJ that is written for healthcare professionals.</td>
                        </tr>
                        <tr styleCode="Botrule Last">
                           <td styleCode="Lrule Rrule" colspan="3" align="left">
                              <paragraph styleCode="First SageBodyText">
                                 <content styleCode="bold">What are the ingredients in REVUFORJ?</content>
                              </paragraph>
                              <paragraph styleCode="SageBodyText">
                                 <content styleCode="bold">Active ingredient</content>: revumenib</paragraph>
                              <paragraph styleCode="SageBodyText">
                                 <content styleCode="bold">Inactive ingredients</content>: microcrystalline cellulose, dicalcium phosphate, crospovidone, hypromellose, sodium bicarbonate, hydrophobic colloidal silica, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and red iron oxide.</paragraph>
                              <paragraph styleCode="SageBodyText">The 110 mg tablet also includes yellow iron oxide.</paragraph>
                              <paragraph styleCode="SageBodyText">The 160 mg tablet also includes FD&amp;C blue #2/indigo carmine aluminum lake.</paragraph>
                              <paragraph styleCode="SageBodyText"/>
                              <paragraph styleCode="SageBodyText">Manufactured for: Syndax Pharmaceuticals, Inc., New York, NY 10017</paragraph>
                              <paragraph styleCode="SageBodyText">REVUFORJ ® is a registered trademark of Syndax Pharmaceuticals, Inc.</paragraph>
                              <paragraph styleCode="SageBodyText">Copyright © 2025 Syndax Pharmaceuticals, Inc.</paragraph>
                              <paragraph styleCode="SageBodyText">For more information, go to <linkHtml href="http://www.revuforj.com/">www.revuforj.com</linkHtml> or call Syndax at 1-888-539-3REV.</paragraph>
                              <paragraph styleCode="SageBodyText">218944-SYND-MG-002 </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250422"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5d43c3b2-346e-4643-91a0-48f55b1d9a1f"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <paragraph/>
                  <table width="100%">
                     <colgroup>
                        <col width="30%" align="left" valign="top"/>
                        <col width="70%" align="center" valign="top"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule First">
                           <td colspan="2" align="center">
                              <content styleCode="bold">INSTRUCTIONS FOR USE<br/>REVUFORJ (REV-you-forge)<br/>revumenib<br/>tablets, for oral use</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">Read these Instructions for Use to prepare and take or give a dose of REVUFORJ tablets broken apart (dispersed) in water and each time you or your child get a prescription refill. There may be new information. This information does not take the place of talking with your healthcare provider about you or your child’s medical condition or your treatment.<br/>
                              <br/>
                              <content styleCode="bold">Important information you need to know before preparing to break apart the REVUFORJ tablets in water:</content>
                              <br/>
                              <list listType="unordered">
                                 <item>For more information about REVUFORJ tablets, see the Medication Guide.</item>
                                 <item>
                                    <content styleCode="bold">REVUFORJ tablets broken apart in water should be prepared for people who are unable to swallow whole REVUFORJ tablets. People who can swallow the tablets whole should not cut, chew, or break the tablets apart in water.</content>
                                 </item>
                                 <item>Take or give REVUFORJ tablets exactly as your healthcare provider tells you to. <content styleCode="bold">Do not</content> change your dose or stop taking REVUFORJ unless your provider tells you to.</item>
                                 <item>REVUFORJ tablets come in different strengths. Each strength is a different color. Your healthcare provider may prescribe more than 1 strength of REVUFORJ tablets for you, so it is important that you understand how to take your medicine the right way. Be sure that you understand exactly how many tablets you need to take, and what strengths to take.</item>
                                 <item>Check the expiration date on the REVUFORJ tablet bottles. <content styleCode="bold">Do not</content> use REVUFORJ if the expiration date on the bottles have passed. Contact your healthcare provider or pharmacist.</item>
                                 <item>The REVUFORJ tablets should be crushed in a clean and dry pill crusher.</item>
                                 <item>Use room temperature water to dissolve the REVUFORJ tablets.</item>
                                 <item>Use a teaspoon to measure the room temperature water. Use a 20 mL oral syringe to administer the medicine.<br/>o Oral syringes can look different. Talk to your pharmacist if you are not sure if you have the correct oral syringe size.<br/>o Replace the oral syringe if there are signs of damage. <content styleCode="bold">See Step 15</content>.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <content styleCode="bold">Supplies needed to prepare and break apart the REVUFORJ tablets in water. You will need to get the 20 mL oral syringe and pill crusher, which are available from your pharmacy.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <content styleCode="bold">Figure A</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <paragraph>
                                 <renderMultiMedia referencedObject="L0874b788-172b-40d2-a9b9-1615d71201bd"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <content styleCode="bold">Preparing to dissolve the REVUFORJ tablets</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left">
                              <paragraph>
                                 <content styleCode="bold">Step 1</content>: Gather and place the REVUFORJ bottles and supplies on a clean, flat surface.</paragraph>
                              <paragraph/>
                              <paragraph>Check your prescribed dose. Count out the strengths and number of REVUFORJ tablets needed for the prescribed dose.</paragraph>
                              <paragraph/>
                              <paragraph>Add all the REVUFORJ tablets to a clean and dry pill crusher. Screw the top of the pill crusher down until it touches the REVUFORJ tablets.</paragraph>
                              <paragraph>
                                 <br/>Turn the pill crusher cap back and forth to crush the REVUFORJ tablets. Continue turning the pill crusher cap back and forth, increasing the crushing pressure on the REVUFORJ tablets each time.</paragraph>
                              <paragraph>
                                 <br/>Repeat until all large REVUFORJ tablet pieces are broken up. The crushed REVUFORJ tablets should be like the consistency of flour.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figb">
                                 <content styleCode="bold">Figure B</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="L7e3c12d1-8405-4490-9a09-9ec97b45c4a7"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 2</content>: Use <content styleCode="bold">two</content> teaspoons to measure 10 mL of room temperature water. Add the 10 mL of water to the small cup. </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Add water to the cup first and then add the crushed REVUFORJ tablets.</content>
                              </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Do not add the crushed REVUFORJ tablets first followed by the room temperature water.</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figc">
                                 <content styleCode="bold">Figure C</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="Lf28b1dd4-5aa2-42b8-b5f0-1f8c755b222f"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 3</content>: Tip the crushed REVUFORJ tablets from the pill crusher into the small cup that contains 10 mL of water. Carefully add all of the crushed REVUFORJ tablets to the small cup.</paragraph>
                              <paragraph>
                                 <br/>Hold the pill crusher upside down over the small cup. Tap the pill crusher to make sure no more crushed REVUFORJ tablet pieces are left in the pill crusher.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figd">
                                 <content styleCode="bold">Figure D</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="L5e8cd5db-6cf1-4570-a171-0052c21867dc"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" scope="row" align="left" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 4</content>: Carefully swirl the cup right after adding the crushed REVUFORJ tablets to the small cup with water. Swirl the small cup every 30 seconds to 1 minute for a total of <content styleCode="bold">5 minutes</content>.</paragraph>
                              <paragraph>
                                 <br/>The crushed REVUFORJ tablets in water will look cloudy.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="fige">
                                 <content styleCode="bold">Figure E</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="La24f9be6-f26d-400d-8dc9-97a16d40ae3b"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 5</content>: Draw up the medicine into the 20 mL oral syringe right away.</paragraph>
                              <paragraph>
                                 <br/>Push the plunger of the oral syringe all the way up towards the tip. Place the tip of the oral syringe in the small cup. Pull the oral syringe plunger to draw up all of the medicine in the small cup.</paragraph>
                              <paragraph>
                                 <br/>The medicine must be taken within <content styleCode="bold">2 hours</content> of preparation. Turn the oral syringe upside down and back several times before taking or giving the medicine.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figf">
                                 <content styleCode="bold">Figure F</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="L3876ed21-b23d-4a02-9924-0c04034d5fa8"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left">
                              <paragraph>
                                 <content styleCode="bold">Step 6</content>: The adult or child should sit up straight or stand before taking the medicine.</paragraph>
                              <paragraph>
                                 <br/>Place the tip of the oral syringe into the mouth against the inside of the cheek. Slowly and gently press down on the plunger to gently squirt the medicine into the mouth.</paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content>Allow the adult or child to swallow the medicine. Make sure that no medicine is left in the mouth.</content>
                              </paragraph>
                              <paragraph/>
                              <paragraph>The adult or child should remain sitting up straight or standing for 2 to 3 minutes right after receiving a dose of the medicine.</paragraph>
                              <paragraph>
                                 <br/>If the medicine is vomited or all of the medicine is not swallowed, do not give another dose. Wait until the next scheduled dose.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figg">
                                 <content styleCode="bold">Figure G</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="La25e4cc5-7438-4ec6-9ea3-a32d3a4706df"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left">
                              <paragraph>
                                 <content styleCode="bold">Step 7</content>: The small cup must be rinsed to make sure the adult or child receives the full dose of REVUFORJ tablets.</paragraph>
                              <paragraph>
                                 <br/>Place <content styleCode="bold">two</content> teaspoons (10 mL) of room temperature water in the cup rinsing down the sides (Figure H)).</paragraph>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph>Swirl the water around the sides of the small cup to make sure any remaining crushed REVUFORJ tablets is mixed with the water (Figure I).</paragraph>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                              <paragraph/>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figh">
                                 <content styleCode="bold">Figure H</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="Ldf671cb3-0933-4924-87c6-fc325aac5bc4"/>
                              </paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Figure I</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="L92799d1b-2a28-4a14-8c59-4ff0c817acc9"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center">
                              <content styleCode="bold">Step 8</content>: Repeat<content styleCode="bold"> Step 5</content> and <content styleCode="bold">Step 6 until no more medicine is left in the cup</content>.</td>
                           <td styleCode="Lrule Rrule" align="center"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">Cleaning the oral syringe after use</content>
                              </paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <paragraph/>
                              <paragraph>Follow the instructions below for cleaning and storing the oral syringe (<content styleCode="bold">Step 9 through Step 15</content>). Throw away the oral syringe in your household trash if it is damaged (<content styleCode="bold">See Step 15</content>), and use a new 20 mL oral syringe.</paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <content styleCode="bold">Step 9: </content>Remove the plunger from the barrel of the oral syringe.</td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figi">
                                 <content styleCode="bold">Figure J</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="L192b5f8b-2711-406a-a3f5-87367f2941ad"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Step 10</content>: Rinse the barrel and plunger in warm running water to help make sure all of the medicine has been removed from the oral syringe.</paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Do not</content> boil the oral syringe.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figj">
                                 <content styleCode="bold">Figure K</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="Labeb1182-496f-4ede-9f11-2bed197756ff"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <content styleCode="bold">Step 11</content>: Put the plunger into the barrel of the oral syringe.</td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figk">
                                 <content styleCode="bold">Figure L</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="L69281cee-8ca9-4f7e-bd35-f2dbf9fa48a9"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <content styleCode="bold">Step 12</content>: Hold the oral syringe tip under water and draw warm water several times into the oral syringe and squirt out again until all of the medicine has been removed from the oral syringe. <content styleCode="bold">Repeat this Step until the oral syringe is clean.</content>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figl">
                                 <content styleCode="bold">Figure M</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="Le0c14f0b-74ab-408a-a295-70958fad2a58"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <content styleCode="bold">Step 13</content>: Remove the plunger from the barrel of the oral syringe. Rinse the barrel and plunger again with warm water.</td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="figm">
                                 <content styleCode="bold">Figure N</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="Lcbe77038-9329-44de-9d11-57dc5364458e"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" valign="top">
                              <content styleCode="bold">Step 14</content>: Shake off excess water or wipe off the outside of the plunger and barrel. Place the barrel and plunger on a clean, dry paper towel to dry.</td>
                           <td styleCode="Rrule" align="center">
                              <paragraph ID="fign">
                                 <content styleCode="bold">Figure O</content>
                                 <br/>
                                 <renderMultiMedia referencedObject="Ld43325ea-8050-47a7-b4a5-4e721857c818"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">Step 15:</content> Make sure the oral syringe parts are fully dry before putting the plunger back into the barrel of the oral syringe. Store the oral syringe in a clean place until the next use.</paragraph>
                              <paragraph/>
                              <paragraph>Replace the oral syringe if:</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>there is any damage to the barrel, plunger, or tip.</item>
                                 <item>you cannot see the dosage markings or it becomes difficult to move the plunger.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <content styleCode="bold">Cleaning the pill crusher after use</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <content styleCode="bold">Step 16</content>: Rinse both parts of the pill crusher with water after use. Shake off excess water or wipe both parts of the pill crusher. Place both parts of the pill crusher on a clean, dry paper towel to dry.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Storing REVUFORJ</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Store REVUFORJ at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Keep the tablets in the bottle that it comes in until you are ready to take it.</item>
                     <item>The REVUFORJ bottle has a drying agent (desiccant) and child resistant closure.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep REVUFORJ and all medicines out of reach of children.</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Manufactured for: Syndax Pharmaceuticals, Inc., New York, NY 10017<br/>REVUFORJ ® is a registered trademark of Syndax Pharmaceuticals, Inc.<br/>Copyright © 2025 Syndax Pharmaceuticals, Inc.<br/>For more information, go to www.revuforj.com or call Syndax at 1-888-539-3REV.<br/>218944-SYND-IFU-002</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph/>
                  <paragraph>Revised: 04/2025</paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="L0874b788-172b-40d2-a9b9-1615d71201bd">
                     <text>Figure A</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure A.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L7e3c12d1-8405-4490-9a09-9ec97b45c4a7">
                     <text>Figure B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure B.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lf28b1dd4-5aa2-42b8-b5f0-1f8c755b222f">
                     <text>Figure C</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure C.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L5e8cd5db-6cf1-4570-a171-0052c21867dc">
                     <text>Figure D</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure D.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="La24f9be6-f26d-400d-8dc9-97a16d40ae3b">
                     <text>Figure E</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure E.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L3876ed21-b23d-4a02-9924-0c04034d5fa8">
                     <text>Figure F</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure F.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="La25e4cc5-7438-4ec6-9ea3-a32d3a4706df">
                     <text>Figure G</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure G.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Ldf671cb3-0933-4924-87c6-fc325aac5bc4">
                     <text>Figure H</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure H.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L92799d1b-2a28-4a14-8c59-4ff0c817acc9">
                     <text>Figure I</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure I.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L192b5f8b-2711-406a-a3f5-87367f2941ad">
                     <text>Figure J</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure J.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Labeb1182-496f-4ede-9f11-2bed197756ff">
                     <text>Figure K</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure K.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L69281cee-8ca9-4f7e-bd35-f2dbf9fa48a9">
                     <text>Figure L</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure L.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Le0c14f0b-74ab-408a-a295-70958fad2a58">
                     <text>Figure M</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure M.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lcbe77038-9329-44de-9d11-57dc5364458e">
                     <text>Figure N</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure N.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Ld43325ea-8050-47a7-b4a5-4e721857c818">
                     <text>Figure O</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure O.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Le04c8cba-4262-421c-bd46-40a5f7ab4072">
               <id root="2bec59c0-b4b9-49de-ae38-9a0f193a8abf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Revuforj 25 mg carton/container labels</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="L758dce8f-3557-4a4e-a073-2a6b0cfcb59b"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Principle Display Panel</content>
                  </paragraph>
                  <paragraph>30 tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">Revuforj®</content>
                     <br/>(revumenib) tablets</paragraph>
                  <paragraph>25 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense enclosed Medication Guide to each patient.</content>
                  </paragraph>
                  <paragraph>Swallow tablets whole or crush and disperse in water.<br/>Do not cut or chew tablets.</paragraph>
                  <paragraph>Syndax                                 Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L7b408496-5508-4bc9-b95c-b870386f1fa1"/>
                  </paragraph>
                  <paragraph>This bottle contains 30 tablets (25 mg each) of                       Revuforj®<br/>revumenib. Swallow tablets whole or crush and                      (revumenib) tablets        Keep out of<br/>disperse in water. Do not cut or chew tablets.                         25 mg                          the reach of<br/>Store at 20°C to 25°C (68°F to 77°F); excursions                                                            children.<br/>permitted between 15°C to 30°C (59°F to 86°F).<br/>Recommended dosage: See Prescribing information.<br/>Manufactured for: Syndax Pharmaceuticals, Inc.                    Syndax          Rx Only        30 tablets</paragraph>
               </text>
               <effectiveTime value="20241113"/>
               <component>
                  <observationMedia ID="L758dce8f-3557-4a4e-a073-2a6b0cfcb59b">
                     <text>Revuforj 25 mg Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Revuforj 25 mg Carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L7b408496-5508-4bc9-b95c-b870386f1fa1">
                     <text>Revuforj 25 mg Container</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Revuforj 25 mg Container.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L86e14a29-edd2-4653-97ce-8cb95f2d1d24">
               <id root="c6a37b88-334d-4114-ad5e-4198ea89ce1b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Revuforj 110 mg carton/container labels</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="L6d9ffdba-b00a-442b-8b8f-4719ddc1039c"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Principle Display Panel</content>
                  </paragraph>
                  <paragraph>30 tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">Revuforj®</content>
                     <br/>(revumenib) tablets</paragraph>
                  <paragraph>110 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense enclosed Medication Guide</content>
                     <br/>
                     <content styleCode="bold">to each patient.</content>
                  </paragraph>
                  <paragraph>Swallow tablets whole or crush and<br/>disperse in water. Do not cut or<br/>chew tablets.</paragraph>
                  <paragraph>Syndax                         Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L7d499c44-4bc3-4a35-8caa-b34977f99c22"/>
                  </paragraph>
                  <paragraph>This bottle contains 30 tablets<br/>(110 mg each) of revumenib.                                      30 tablets</paragraph>
                  <paragraph>Swallow tablets whole or crush<br/>and disperse in water. Do not cut or<br/>chew tablets.                                                             <content styleCode="bold">Revuforj®</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F);                         (revumenib) tablets<br/>excursions permitted between 15°C<br/>to 30°C (59°F to 86°F).                                              110 mg</paragraph>
                  <paragraph>Recommended dosage:<br/>See Prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>                                                    Syndax                  Rx Only<br/>Syndax Pharmaceuticals, Inc.</paragraph>
               </text>
               <effectiveTime value="20241113"/>
               <component>
                  <observationMedia ID="L6d9ffdba-b00a-442b-8b8f-4719ddc1039c">
                     <text>Revuforj 110 mg Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Revuforj 110 mg Carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L7d499c44-4bc3-4a35-8caa-b34977f99c22">
                     <text>Revuforj 110 mg Container</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Revuforj 110 mg Container.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L855ea21d-12f3-4fb6-bf32-35af353d4713">
               <id root="aae8b358-3e1e-44f5-899c-026d2e8717ac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Revuforj 160 mg carton/container labels</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="Laae09461-70b1-45dc-a27d-afc9d59c3104"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Principle Display Panel</content>
                  </paragraph>
                  <paragraph>30 tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">Revuforj®</content>
                     <br/>(revumenib) tablets</paragraph>
                  <paragraph>160 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense enclosed Medication Guide</content>
                     <br/>
                     <content styleCode="bold">to each patient.</content>
                  </paragraph>
                  <paragraph>Swallow tablets whole or crush and<br/>disperse in water. Do not cut or<br/>chew tablets.</paragraph>
                  <paragraph>Syndax                                   Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L7fe67b59-a4bd-471d-a35a-ddd513cf3bb5"/>
                  </paragraph>
                  <paragraph>This bottle contains 30 tablets<br/>(160 mg each) of revumenib.                                         30 tablets</paragraph>
                  <paragraph>Swallow tablets whole or crush<br/>and disperse in water. Do not cut or<br/>chew tablets.                                                      <content styleCode="bold">        Revuforj®</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F);                         (revumenib) tablets<br/>excursions permitted between 15°C<br/>to 30°C (59°F to 86°F).                                              160 mg</paragraph>
                  <paragraph>Recommended dosage:<br/>See Prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>                                                    Syndax                Rx Only<br/>Syndax Pharmaceuticals, Inc.</paragraph>
               </text>
               <effectiveTime value="20241119"/>
               <component>
                  <observationMedia ID="Laae09461-70b1-45dc-a27d-afc9d59c3104">
                     <text>Revuforj 160 mg Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Revuforj 160 mg Carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L7fe67b59-a4bd-471d-a35a-ddd513cf3bb5">
                     <text>Revuforj 160 mg Container</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Revuforj 160 mg Container.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>